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Giant axonal neuropathy (GAN) is an early-onset neurological disorder caused by mutations in the GAN gene 
(encoding for gigaxonin), which is predicted to be an E3 ligase adaptor. In GAN, aggregates of intermediate 
filaments (IFs) represent the main pathological feature detected in neurons and other cell types, including 
patients’ dermal fibroblasts. The molecular mechanism by which these mutations cause IFs to aggregate is 
unknown. Using fibroblasts from patients and normal individuals, as well as Gan–/– mice, we demonstrated 
that gigaxonin was responsible for the degradation of vimentin IFs. Gigaxonin was similarly involved in the 
degradation of peripherin and neurofilament IF proteins in neurons. Furthermore, proteasome inhibition 
by MG-132 reversed the clearance of IF proteins in cells overexpressing gigaxonin, demonstrating the involve-
ment of the proteasomal degradation pathway. Together, these findings identify gigaxonin as a major factor in 
the degradation of cytoskeletal IFs and provide an explanation for IF aggregate accumulation, the subcellular 
hallmark of this devastating human disease.
Introduction
Abnormal aggregates of intermediate filaments (IFs) are patholog-
ical hallmarks of tissue-specific diseases, including keratin aggre-
gates in Mallory bodies in diseased hepatocytes (1); Rosenthal 
fibers in the glial cells of Alexander disease patients, which contain 
glial fibrillary acidic protein (GFAP) (2); and neuronal IF aggregates 
in the neurons of patients with amyotrophic lateral sclerosis (ALS), 
Alzheimer’s disease (3), Parkinson’s disease, dementia with Lewy 
bodies, neuronal IF inclusion disease (NIFID), giant axonal neu-
ropathy (GAN) (4–6), some forms of Charcot-Marie-Tooth disease 
(CMT), diabetic neuropathy, and spinal muscular atrophy (7, 8). 
Although numerous mutant genes have been identified that 
cause these diseases, few have provided insights into the mecha-
nisms responsible for IF aggregate formation. GAN is unique with 
respect to these diseases, as it affects numerous classes of cytoskel-
etal IFs (4–6, 9–15). We therefore reasoned that a detailed analysis 
of this disease might provide insights into common mechanisms 
responsible for the formation of IF aggregates in different tissues 
of GAN patients and into the regulation of the turnover of this 
major class of cytoskeletal proteins.
GAN is a recessive disease (4, 5, 16, 17) caused by mutations in the 
GAN gene (encoding for gigaxonin), which is located on chromo-
some 16q24. Over 30 distinct mutations distributed throughout 
the GAN gene have been identified (9, 11, 16). GAN patients are 
born apparently normal, but typically by 3–5 years of age, they dis-
play progressive muscle weakness, diminished tendon reflexes, and 
pronounced gait disturbances. Subsequently, they become wheel-
chair bound, experience dysmetria and seizures, and ultimately 
require feeding and breathing tubes. Patients typically die during 
the second or third decade of life. Histopathology reveals the pres-
ence of large axonal swellings (“giant axons”) filled with type IV 
neuronal IFs — the neurofilament (NF) triplet proteins NF light, 
medium, and heavy chain (NF-L, NF-M, and NF-H, respectively) — 
in the CNS and peripheral nervous system (PNS) (4, 5, 18). In addi-
tion to the NF triplet proteins, the type III IF protein peripherin 
is also a component of the endogenous IF networks in neurons of 
the PNS (19). Thus, it is likely that the aggregates detected in the 
giant axons of PNS neurons in GAN patients contain both the trip-
let proteins and peripherin. Most patients also have characteristic 
kinky hair, which suggests that type I and II keratin IFs are affected 
(12, 13). Moreover, as first shown more than 30 years ago by Pena 
(6, 15) and subsequently verified by others (10, 20–22), cultured 
skin fibroblasts from patients contain large IF aggregates of type III 
vimentin (encoded by VIM) (6, 10, 15, 20–22), and similar IF aggre-
gates have been detected in Schwann cells, melanocytes, endothelial 
cells, muscle cells, and Langerhans cells (14, 23). Taken together, 
these observations suggest that gigaxonin mutations affect many 
members of the cytoskeletal IF protein family.
Based on sequence homology, gigaxonin appears to be an E3 
ubiquitin ligase adaptor and thus is likely involved in degrading 
protein substrates via the ubiquitin-proteasome system (UPS). 
Gigaxonin belongs to the BTB-KELCH domain family of adaptor 
proteins. The KELCH domain interacts with the protein targeted 
for degradation, whereas the BTB domain interacts with the Cul-
lin-3 component of the ubiquitin ligase complex (24–27). In sup-
port of gigaxonin’s role in regulating the turnover of IF proteins, 
histological examination of Gan–/– mice has revealed pathological 
features similar to those found in GAN patients. These include 
accumulation of IF proteins, formation of aggregates in the ner-
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vous system, loss of peripheral axons, and muscle atrophy (28, 29). 
Further evidence supporting a role for gigaxonin in regulating IF 
protein levels is based on quantitative measurements in Gan–/– 
mice, which have shown up to a 7-fold increase in IF protein levels 
in the brain, cerebellum, and spinal cord (28, 29). Importantly, the 
increase in the levels of IF proteins is not associated with a corre-
sponding increase of IF mRNAs (28). Together, these results sug-
gest that complete elimination of gigaxonin leads to increased IF 
protein levels with subsequent aggregation.
Even though the major alterations that take place in the cells 
of GAN patients appear to involve IFs (10, 15, 20), it has been 
reported that gigaxonin is involved in degradation of the micro-
tubule-associated proteins MAP1B (30), MAP8 (31), and tubulin 
folding cofactor B (TBCB) (32). However, other studies have shown 
that microtubules (MTs) appear normal (15) and TBCB levels are 
not altered in GAN cells (20). Similarly, the relative amounts of 
MAP1B, MAP8, and TBCB do not increase in GAN mouse models 
that display a dramatic alteration in NF organization (29). Fur-
thermore, Pena previously provided evidence that actin networks 
appear normal in GAN cells (15).
Here, we focused our attention on the mechanisms responsible for 
the alterations in IF organization using fibroblasts obtained from 
GAN patients. These cells provide a useful experimental model 
since they can be cultured easily and they contain large vimentin 
IF (VIF) aggregates that resemble the NF aggregates seen in nerve 
cell axons. Our present findings showed that the most likely mecha-
nism responsible for the aggregates of IFs in GAN is attributable to 
a critically important role for gigaxonin in regulating the levels of IF 
proteins via a proteasomal-dependent degradation pathway.
Results
VIFs are aggregated in GAN patients’ cells. Fibroblasts derived from 
skin biopsies taken from 3 GAN patients (referred to herein as 
GAN cells) were studied by immunofluorescence to determine the 
organization of VIF. The majority of GAN cells contained unusu-
ally thick bundles of VIF not seen in control cells. In addition to 
these bundles, GAN cells frequently contained large perinuclear 
aggregates (Figure 1A). The number of cells containing aggregates 
increased as a function of passage number in culture. For exam-
ple, in GAN cell line 08F699 (having mutations IVS6_1g_a and 
L510X), approximately 20.89% ± 2.05% of cells (n = 300) contained 
VIF aggregates at passage 3, whereas at passage 9, approximately 
50.9% ± 4.25% had aggregates (P = 0.0069; n = 300), as determined 
by immunofluorescence. Transmission EM (TEM) confirmed the 
presence of large accumulations of 10-nm-diameter VIFs in jux-
tanuclear aggregates and unusually thick IF bundles dispersed 
throughout the cytoplasm (Figure 1B and data not shown). Fur-
ther confirmation of the polymerized state of vimentin in GAN 
cells was obtained from biochemical analyses of IF-enriched cyto-
skeletal preparations (33). Virtually all of the vimentin was in 
low-speed pellet fractions, indistinguishable from controls and 
demonstrating its insoluble polymerized form, with almost no 
detectable vimentin in the supernatant (data not shown).
Frequently, mitochondria were found either embedded in or 
surrounding the VIF aggregates (Figure 1B). Many of these mito-
chondria were abnormally swollen with reduced numbers of cris-
tae (data not shown). Elements of the smooth and rough endo-
plasmic reticulum were also seen surrounding or within the VIF 
aggregates (Figure 1B). In contrast to the dramatic changes seen 
in VIF in GAN cells, actin/microfilament (actin/MF) organization 
and MTs were indistinguishable from controls, as determined by 
fluorescence microscopy (Figure 1C). Quantitative immunoblot-
ting of the GAN cell lines showed that the levels of vimentin com-
pared with controls varied from 0.6- to 1.6-fold (Figure 1D). Of the 
3 lines, 2 contained increased levels of vimentin; however, it is not 
presently clear whether these differences are functionally relevant.
VIF are also aggregated in Gan–/– mouse embryonic fibroblasts. Because 
defective gigaxonin has a major effect on VIF organization in GAN 
cells, we hypothesized that the complete elimination of gigaxonin 
should have similar effects on cells derived from mouse models. 
Indeed, Gan–/– mouse embryonic fibroblasts (MEFs) (28) contained 
VIF aggregates that also increased as a function of passage num-
ber (passage 3, ∼21.4% ± 1.1%, n = 315; passage 6, ∼47.5% ± 0.30%, 
n = 475; P = 0.00047), as assessed by both light microscopy and 
EM (Figure 1, E and G). EM revealed that IF aggregates in Gan–/– 
MEFs appeared similar to those observed in GAN cells (Figure 1G). 
In addition, MTs and MFs appeared normal in these MEFs, and 
their vimentin levels were similar to those of controls (Figure 1, F 
and H). Thus, either disease-causing mutations in gigaxonin or its 
complete knockout caused abnormal aggregates of VIF.
Expression of WT gigaxonin causes loss of VIF networks and clearance of 
vimentin from cells. Given our observations that mutations in or dele-
tions of gigaxonin caused IF aggregation, we sought to test the pos-
sibility that restoration of normal VIF networks might be achieved 
by introducing WT gigaxonin into GAN cells or Gan–/– MEFs. How-
ever, we found that expressing WT gigaxonin did not just clear the 
VIF aggregates, but in fact had the more dramatic effect of causing 
almost complete loss of vimentin in both control and GAN cells 
(Figure 2, A, D, and E). Although VIF disappeared by 72 hours, MTs 
and MFs appeared normal (Figure 2, D–F, and refs. 15, 20), and no 
changes in the levels of tubulin and actin were detected by immu-
noblotting (Figure 2A). We also tested whether expression of WT 
gigaxonin resulted in a loss of TBCB, as previously reported (32). 
Immunoblotting revealed no changes in TBCB levels in control or 
GAN cells under the same experimental conditions (Supplemental 
Figure 1; supplemental material available online with this article; 
doi:10.1172/JCI66387DS1). This latter finding confirmed the results 
of other studies (20, 29). To further confirm the role of gigaxonin 
in regulating IF protein levels, a mutant form, S52G gigaxonin (9), 
was expressed in BJ5ta cells. Under these conditions, no change in 
vimentin levels were detected by immunoblotting (Figure 2B and 
Supplemental Figure 2). Thus, this mutant form of gigaxonin, unlike 
WT gigaxonin, could not clear vimentin. Overall, these results dem-
onstrated that gigaxonin has a substantial effect on VIFs, but not on 
the other major cytoskeletal proteins, tubulin and actin.
Because gigaxonin is a putative E3 ligase adaptor, its expression 
is likely to cause IF clearance via a degradative pathway. However, 
in principle, it is also possible that the decrease in vimentin protein 
is caused by a reduction in transcription of VIM mRNA. To test 
this, VIM mRNA levels were determined by RT-PCR after expres-
sion of WT or S52G gigaxonin in BJ5ta cells. Neither WT nor 
mutant gigaxonin had any detectable effect on VIM mRNA levels 
(Figure 2C). This provides further evidence in support of a role for 
gigaxonin in mediating the degradation of vimentin.
Time course of vimentin clearance due to gigaxonin expression. To 
define the time course of the loss of the VIF network and vimentin 
protein clearance, GAN and control cells were analyzed at different 
time points after initiation of gigaxonin expression. Immunoblot-
ting revealed a time-dependent loss of vimentin over 24–72 hours, 
resulting in levels only approximately 8% of those seen in controls 
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(P = 0.00097; compare Figure 3A and Figure 2A). This disappear-
ance of vimentin was inversely related to the time course and levels 
of WT gigaxonin expression. Parallel immunofluorescence stud-
ies showed that at 24 hours after induction of gigaxonin expres-
sion, VIFs were still observed, but by 48 hours, mature IFs disap-
peared, and only short IFs and nonfilamentous vimentin particles 
remained (Figure 3B and ref. 34). By 72 hours, there was no detect-
able vimentin (Figure 3B). These observations suggest that VIF 
Figure 1
VIFs are aggregated in both GAN cells and Gan–/– MEFs. (A) VIF networks in a control (Con) cell and in 2 different GAN cells, the latter of which 
were aggregated into bundles and large bodies (arrows). HM, higher magnification. Representative images, 5 preparations of 3 GAN patient 
lines. (B) TEM showing aggregated VIF in GAN cells. Mitochondrion (M) and elements of the endoplasmic reticulum (arrow) are indicated in the 
right panel. (C) MTs (top) and actin (bottom) in double-stained GAN cells. Representative images, 5 preparations. (D) Western blot analyses of 
control fibroblasts (AG08470) and 3 GAN cell lines. Fold changes (± SD) in GAN line vimentin levels relative to control were as follows: F07476 
(left), 1.623 ± 0.161; 08F699 (middle), 0.687 ± 0.05; F09133 (right), 1.183 ± 0.064 (P = 0.0039). Representative blots, 3 preparations. (E) VIFs 
were only aggregated in Gan–/– MEFs, not WT MEFs. Representative images, 5 preparations. (F) Western blotting of WT and Gan–/– MEF lysates. 
Representative blots, 3 preparations. (G) TEM showing VIF aggregates in Gan–/– MEFs. (H) MT (top) and actin (bottom) organization in Gan–/– 
MEFs. Representative images, 5 preparations. Scale bars: 10 μm (A, C, E, and H); 5.0 μm (B, left, and G, left); 0.5 μm (B, right, and G, right).
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first disassembled into short IFs and nonfilamentous particles 
that were subsequently further degraded. This series of VIF degra-
dation steps was similar for GAN cells and WT and Gan–/– MEFs 
(Figure 3, C–E). These observations also demonstrated that in 
GAN cells and Gan–/– MEFs, the aggregates were the last vimentin 
structures to disappear after gigaxonin expression (Figure 3, C and 
E), most likely attributable to the high concentration of VIF in the 
aggregates relative to the rest of the cell. In contrast, time course 
analysis after S52G gigaxonin expression in BJ5ta cells revealed 
no change in vimentin protein levels and no obvious structural 
changes in VIF (Figure 2B and Supplemental Figure 2, A and B). 
These results confirmed that disease-causing mutations in gigaxo-
nin result in the loss of its function, insofar as its ability to clear 
vimentin is concerned.
Interactions between gigaxonin and vimentin. With respect to the localiza-
tion of gigaxonin, immunofluorescence revealed that it was evenly dis-
tributed throughout the cytoplasm in control cells. However, in GAN 
cells, gigaxonin was concentrated in the VIF aggregates (Figure 4A). 
Therefore, we sought to determine whether gigaxonin interacts with 
vimentin in co-IP experiments. WT gigaxonin was expressed in BJ5ta 
cells for 36 hours, a time point at which cells still contained vimentin 
(Figure 3A). Cells were lysed at this time, and IP using anti-gigaxonin 
Figure 2
Gigaxonin expression causes vimentin clearance. (A) Immunoblotting 
of control and GAN cells 72 hours after initiating expression of vec-
tor control (Vec) or FLAG-tagged WT gigaxonin (Gig). Representative 
blots, 4 experiments. (B) Immunoblotting of cells expressing vector or 
FLAG-tagged S52G gigaxonin (S52G Gig). Representative blots, 3 
experiments. (C) RT-PCR analysis of VIM mRNA in BJ5ta cells. Average 
data ± SD, 3 experiments. Fold increases relative to control (normalized 
to 1) were as follows: mock, 0.92 ± 0.268; WT gigaxonin (P = 0.6459 
vs. mock), 1.04 ± 0.321; S52G gigaxonin, 1.1 ± 0.135 (P = 0.3588 vs. 
mock). (D and E) Immunofluorescence of (D) BJ5ta cells and (E) GAN 
cells, 72 hours after initiating expression of vector or WT gigaxonin, with 
anti-FLAG and anti-vimentin or anti-tubulin (MT). Overlays are shown 
at right (F, FLAG; V, vimentin). Representative images, 5 preparations. 
(F) BJ5ta (top) and GAN (bottom) cells stained for gigaxonin and actin 
after 72-hour expression of WT gigaxonin. Overlays are shown at right. 
Representative images, 4 preparations. Scale bars: 10 μm (D–F).
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antibodies revealed the presence of vimentin by immunoblotting, 
and the reciprocal experiment (IP using anti-vimentin) showed the 
presence of gigaxonin (Figure 4, B and C). Additional evidence for 
an interaction between gigaxonin and vimentin in cell lysates was 
obtained using ELISA (Figure 4D). Taken together, these results 
revealed an interaction between vimentin and gigaxonin. However, 
further studies are required to determine whether this interaction is 
direct or mediated by other proteins. In addition, we do not know the 
assembly state of vimentin involved in the interaction with gigaxonin 
under normal in vivo physiological conditions. In IP experiments, 
vimentin was completely solubilized in the RIPA buffer used to opti-
mize conditions for vimentin/gigaxonin interactions.
The central rod domain of vimentin is required for its clearance by gigaxo-
nin. In order to identify which region of vimentin is important for 
its clearance by gigaxonin, FLAG-tagged deletion constructs of 
its 3 major domains (Figure 4E) were prepared: the non–α-helical 
Figure 3
Time course of VIF changes after WT gigaxonin expression. (A) Quantitative immunoblot analyses of lysates from BJ5ta cells prepared 0, 24, 
48, and 72 hours after initiation of WT gigaxonin expression. Vimentin, tubulin, and actin were detected with specific antibodies, and gigaxonin 
was detected with anti-FLAG. Vimentin levels decreased to 88% ± 7.7%, 37.5% ± 3.7%, and 7.7% ± 4.5% of controls after 24, 48, and 72 hours, 
respectively (P = 0.00097). Representative blots, 3 experiments. (B) BJ5ta cells were fixed 24, 48, and 72 hours after initiation of WT gigaxonin 
expression and were double labeled with anti-FLAG and anti-vimentin. Vimentin staining patterns of boxed regions are shown at higher mag-
nification below (enlarged approximately ×5-fold): VIFs were still intact at 24 hours, whereas at 48 hours, vimentin was mainly present as short 
filaments and particles. (C–E) Time course of vimentin clearance, assessed by immunofluorescence, in (C) GAN cells, (D) WT MEFs, and (E) 
Gan–/– MEFs. Cells were fixed 24, 48, and 72 hours after initiation of WT gigaxonin expression and were double labeled with anti-FLAG and anti-
vimentin. Representative images, 4 experiments. Scale bars: 10 μm (B–E).
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N-terminal domain (referred to herein as the FLAG-ΔN-VIM con-
struct), the non–α-helical C-terminal domain (FLAG-ΔC-VIM), 
and the central rod domain, with both the N- and C-termini 
deleted (FLAG-Rod-VIM). These constructs were used to establish 
lines of mouse 3T3 fibroblasts. After expression of WT gigaxonin 
for 72 hours, all 3 deletion constructs of vimentin were cleared, 
as determined by immunoblotting. As expected, the endogenous 
full-length vimentin was also cleared within these same cells 
(Figure 4F). These results suggest that, as the common domain 
in all 3 deletion constructs, the central rod domain of vimentin is 
required for its clearance by gigaxonin (Figure 4, E and F).
Additionally, we expressed FLAG-tagged non–α-helical N and C 
termini alone (referred to herein as Head and Tail, respectively). 
We found that the FLAG-Head-VIM and FLAG-Tail-VIM con-
structs could only be expressed at extremely low levels in 3T3 cells, 
undetectable by immunoblotting; by immunofluorescence, they 
were mainly associated with the endogenous VIF network (data 
not shown). Therefore, we prepared FLAG-Head-VIM and FLAG-
Tail-VIM deletion construct–expressing lines using Vim–/– MEFs in 
order to visualize them by immunofluorescence in the absence of 
an extensive endogenous VIF network (see Methods). As a further 
control, we also prepared individual lines of Vim–/– MEFs express-
Figure 4
Gigaxonin interacts with vimentin, peripherin, and NF-L. (A) Control and GAN cells double labeled with anti-gigaxonin and anti-vimentin. Associa-
tion between gigaxonin and vimentin was only observed in the GAN cell aggregates. Representative images, 4 preparations for each of 3 GAN 
cell lines. (B) IPs using anti-gigaxonin were blotted with anti-vimentin. I, input (cell lysate). Rabbit IgG was used as control (M). Representative 
blot, 3 experiments. (C) IPs using anti-vimentin were blotted with anti-gigaxonin. Mouse IgG was used as control (M). Representative blot, 3 
experiments. Lanes were run on the same gel but were noncontiguous (black lines). (D) ELISA demonstrated that gigaxonin bound to purified 
vimentin and the vimentin rod domain. Average data, 3 experiments. (E) Schematic of the vimentin deletion constructs FLAG-FL-VIM, FLAG-ΔC-
VIM, FLAG-ΔN-VIM, FLAG-Rod-VIM, FLAG-Head-VIM, and FLAG-Tail-VIM. (F) Immunoblotting of lysates from 3T3 cell lines with FLAG-ΔC-VIM, 
FLAG-Rod-VIM, and FLAG-ΔN-VIM after WT gigaxonin expression for 72 hours, using antibodies to vimentin, FLAG (gigaxonin), tubulin, and 
actin. Representative blots, 3 experiments. (G) Immunoblotting of PC12 cell lysates prepared 72 hours after initiating WT gigaxonin expression 
using anti-peripherin, tubulin, actin, and gigaxonin. Similar results were obtained in the absence and presence of NGF. Representative blots, 3 
experiments. (H) Immunoblotting of SH-SY-5Y cell lysates prepared 72 hours after WT gigaxonin expression using antibodies to NF-L, tubulin, 
actin, and gigaxonin. NF-L clearance was the same in undifferentiated (-RA-BDNF) and differentiated (+RA+BDNF) cells. Representative blots, 
3 experiments. Scale bar: 10 μm (A).
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ing FLAG-tagged full-length vimentin (FLAG-FL-VIM), FLAG-
ΔN-VIM, FLAG-ΔC-VIM, and FLAG-Rod-VIM. As expected, FLAG-
ΔC-VIM formed filaments (35, 36), whereas FLAG-ΔN-VIM and 
FLAG-Rod-VIM appeared particulate (nonfilamentous) through-
out the cell (Supplemental Figure 3A). Immunofluorescence con-
firmed that these latter 3 constructs were cleared by gigaxonin 
expression (Figure 4F and Supplemental Figure 3B). The observa-
tion that all 3 constructs were cleared indicates that being incor-
porated into a filament is not essential for degradation, since the 
nonfilamentous forms of vimentin that contained the rod domain 
were efficiently degraded. In contrast, neither the nonfilamentous 
N terminus (FLAG-Head-VIM) nor the C terminus (FLAG-Tail-
VIM) was cleared (Supplemental Figure 3B). These latter con-
structs appeared to be concentrated in the nucleus, most likely 
a result of diffusion reflecting their small size. Together, these 
results provide further evidence that the central rod domain of 
vimentin is required for clearance by gigaxonin. Additional sup-
port for gigaxonin’s interaction with the central rod domain came 
from our ELISA results (Figure 4D). Since the central rod domain 
is highly conserved among all types of cytoskeletal IFs, its interac-
tion with gigaxonin may help to explain both the accumulation 
and the clearance of different IF types in the 
affected cell types in GAN patients and Gan–/– 
mice (see below).
Gigaxonin expression causes clearance of neuron-
specific IFs. Because the neurological conse-
quences of GAN are associated with IF aggre-
gates in the axons of PNS and CNS neurons 
in patients as well as in Gan–/– mice (Supple-
mental Figure 5 and refs. 28, 29), we sought 
to determine whether gigaxonin expression 
can cause the clearance of IFs composed of 
peripherin and the NF triplet proteins. We 
established a PC12 cell line stably expressing 
FLAG-tagged WT gigaxonin. Immunoblot-
ting revealed that expression of gigaxonin 
caused the loss of peripherin in these cells, 
which was not affected by their differentiation 
status (Figure 4G). These results were also 
confirmed by immunofluorescence (Supple-
mental Figure 4, A and B). Similarly, analysis 
of a neuroblastoma cell line, SH-SY-5Y, that 
stably expressed WT gigaxonin revealed clear-
ance of NF-L protein by both immunoblot-
ting and immunofluorescence (Figure 4H and 
Supplemental Figure 4, C and D).
Mechanisms involved in the clearance of vimentin 
by gigaxonin. Based on the primary structure of 
gigaxonin, which predicts that it is an E3 ubiq-
uitin ligase adaptor, and the finding that dif-
ferent types of IF proteins were degraded when 
gigaxonin was expressed in cells, we performed 
additional experiments to determine whether 
gigaxonin-mediated clearance of IF proteins 
involves the UPS. BJ5ta cells that had been 
cleared of vimentin by expression of WT gigax-
onin for 72 hours were treated with MG-132 to 
inhibit proteasomes for 6–12 hours. Prior to 
the addition of MG-132, vimentin levels were 
barely detectable. Immunoblotting showed the 
appearance of increasing amounts of vimentin concomitant with 
6–12 hours of proteasome inhibition (Figure 5A). These experiments 
were not carried out for the longer time periods required to fully 
restore vimentin levels, due to the significant deleterious effects of 
MG-132 on cell viability (37). As a further control, Gan–/– MEFs were 
also treated with MG-132 for 12 hours. Immunoblot analysis showed 
no detectable increase in vimentin (data not shown), which further 
suggests that gigaxonin is essential for vimentin degradation by pro-
teasomes. These findings suggest that the degradation of vimentin 
involves the typical UPS pathway, and it is therefore expected that 
vimentin should be ubiquitinated. Our attempts to show vimentin 
ubiquitination used IP with anti-vimentin or anti-ubiquitin 36 hours 
after gigaxonin expression in BJ5ta cells. In addition, we carried out 
experiments using His-tagged ubiquitin in vivo followed by IP. These 
assays provided no evidence for vimentin ubiquitination in vivo (data 
not shown; see Methods). Therefore, we attempted to use an in vitro 
ubiquitination assay using reticulocyte lysates. Similarly, we could 
not detect ubiquitination of vimentin (Figure 5B).
To determine whether other degradative pathways play a role 
in vimentin clearance, BJ5ta cells were cleared of vimentin by 
expression of WT gigaxonin for 72 hours. Parallel cultures of 
Figure 5
Mechanism responsible for VIF clearance by gigaxonin. (A) Immunoblotting of control and WT 
gigaxonin expressing BJ5ta cells treated with MG-132 using antibodies to vimentin, actin, or 
FLAG (gigaxonin). MG-132 treatment caused substantial recovery of vimentin in gigaxonin-
expressing cells. Representative blots, 4 experiments. (B) In vitro ubiquitination assay show-
ing ubiquitination ladder for the positive control sic 60–barnase–DHFR, but not for vimentin in 
the same preparation. Representative autoradiogram, 3 experiments. Lanes were run on the 
same gel but were noncontiguous (black line). (C) Immunoblotting of lysates of BJ5ta cells that 
had expressed gigaxonin for 72 hours and subsequently were treated with chloroquine (CQ; 
lysosome inhibitor), MG-132 (proteasome inhibitor), or 3-MA (autophagy inhibitor) for 12 hours. 
Blots were probed with antibodies to vimentin, actin, tubulin, or gigaxonin. The untreated 
cell lysate (–) contained very small amounts of vimentin. Vimentin recovery was seen only 
upon inhibition of proteasomes, not by inhibition of lysosomes or autophagy. Representative 
immunoblots, 4 experiments. (D) Longer exposure of the anti-vimentin full-length immunoblot 
in C, showing absence of a typical ubiquitinated protein ladder for vimentin. Representative 
blots from 4 experiments.
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these cells were then separately treated for 12 hours with inhibi-
tors for autophagy (3-methyl adenine; 3-MA) or lysosomal deg-
radation (chloroquine) or with MG-132 as a control. Immunob-
lotting revealed the reappearance of vimentin only with MG-132 
treatment (Figure 5C). It should also be noted that there was no 
evidence for the typical ladder of vimentin — which would indicate 
ubiquitination — when these same samples were immunoblotted 
with anti-vimentin (Figure 5D).
Discussion
Our results showed that the normal function of gigaxonin, a predict-
ed E3 ligase adaptor protein, was to target certain IF proteins (e.g., 
vimentin, peripherin, and NF-L) for degradation. They also provided 
a framework for understanding the molecular basis of the forma-
tion of the large IF aggregates seen in different cell types of GAN 
patients. In both PNS and CNS, large axonal aggregates of IFs are 
the pathological hallmark of GAN. Although the exact mechanism 
behind the formation of these aggregates is not known, our results 
suggest that under normal conditions, gigaxonin regulates the deg-
radation of IF proteins within axons. Therefore, when gigaxonin 
is defective, as in GAN, it leads to local accumulation of IFs along 
axons. Support for this possibility stems from the finding that the 
UPS is present along axons (e.g., ref. 38). Since GAN is a progressive 
disorder beginning at an early age with no detectable phenotype, it 
is likely that giant axons form slowly over prolonged periods begin-
ning in early childhood and into the teenage years. The normal slow 
turnover of IF proteins (39–44) could therefore lead to the gradual 
accumulation of polymerized IFs into aggregates in the absence of 
normally functioning gigaxonin. Support for this possibility comes 
from our observation of GAN patient fibroblasts, which showed a 
passage-dependent increase in the number of cells containing VIF 
aggregates. The formation of large IF aggregates within axons could 
lead to altered axonal transport and progressive neuronal dysfunc-
tion, accounting for the hallmark features of the disease, particularly 
the early-onset neuropathy. In support of defective transport mecha-
nisms, we found accumulation of mitochondria in close proximity to 
and within the IF aggregates. This most likely reflects the previously 
reported interactions, binding, and anchorage of mitochondria to 
both VIFs (45) and NF IFs (46). It is also important to note that the 
nervous system contains both neuronal and glial cells. Therefore the 
glial-specific IF protein GFAP, as well as VIFs in astrocytes (47), could 
also contribute to the GAN phenotype.
The finding that GAN was caused by mutations in a single gene 
suggests that gene replacement may be a successful therapeutic 
approach. Indeed, overexpression of WT gigaxonin did lead to 
the disappearance of VIF aggregates, as well as those containing 
peripherin and NF IFs. Although we did not test whether GFAP 
IFs are cleared in glial cells, it is also conceivable that the similar 
aggregates of this type III IF protein might be cleared by gigaxonin 
in patients with Alexander disease (2). However, as in any gene res-
cue therapy, one must carefully consider dosage, since high levels 
of gigaxonin expression can lead to a complete loss of the normal 
IF system in numerous cell types. Although the overexpression of 
gigaxonin has provided us with the most convincing evidence in 
support of its role in IF protein degradation, it is possible that 
excess expression of gigaxonin may have side effects that we have 
been unable to detect. We feel that this is unlikely, as the over-
expression of gigaxonin for prolonged periods (up to a month) 
had no obvious effects on cell growth (data not shown). We also 
showed that overexpression of the S52G mutant of gigaxonin, at 
the same level as WT gigaxonin overexpression, had no effect on 
the organization of VIF networks, and there was no degradation 
of vimentin. These findings emphasize that the specific targets for 
gigaxonin are members of the cytoskeletal IF protein family. In 
further support of the specificity for IF cytoskeletal systems, we 
could detect no decreases in the level of either tubulin or actin 
when gigaxonin was expressed in cells. However, we did detect an 
increase in the amount of tubulin in GAN cells expressing defective 
gigaxonin, even though the overall organization of MTs appeared 
normal. Based on the well-established interactions between IFs 
and MTs, it is conceivable that alterations in IF protein turnover 
caused by gigaxonin mutations could stimulate tubulin expres-
sion by unknown feedback mechanisms (34, 48–50).
The finding that gigaxonin expression degraded IF proteins was 
consistent with their higher expression levels and IF aggregate for-
mation previously seen in the differentiated tissues of adult Gan–/– 
mice (28, 29). However, the Gan–/– MEFs analyzed in the present 
study showed no difference in vimentin levels compared with WT 
MEFs. This discrepancy may be related to the early developmen-
tal stage at which the MEFs were obtained. For example, there 
could be less accumulation of IFs in embryonic fibroblasts rela-
tive to that seen in adult differentiated cells. The fact that human 
patients appear normal during their first few years of life also sug-
gests that it takes a significant amount of time to accumulate IF 
aggregates within neurons that can cause clinically detectable neu-
rological phenotypes. Further studies are required to understand 
the role and regulation of gigaxonin during early development 
and, in GAN patients, as a function of disease progression.
IFs have been shown to be composed of stable proteins with a 
half-life ranging from 18 hours to 8 days (39–42). However, very 
little is known about the pathways involved in their degradation 
in normal cells. Although our present results demonstrated that 
gigaxonin targets IF proteins for degradation via the UPS, the pre-
cise mechanism for proteasome targeting remains unknown. An 
insight regarding this mechanism comes from the observation 
that numerous nonfilamentous vimentin particles and short IFs 
appeared as the VIF network was being cleared by expressing gigax-
onin. This finding suggests that long mature IFs are first disas-
sembled into smaller structures, which have previously been iden-
tified as assembly/disassembly intermediates (51), before being 
degraded. However it is not known whether short IFs, unit length 
filaments (ULFs), tetramers, dimers, monomers, or other inter-
mediates are targeted for degradation. The mechanism by which 
gigaxonin expression leads to VIF disassembly is also unknown.
It is conceivable that interactions between gigaxonin and vimentin 
participate in VIF disassembly, especially since our evidence suggests 
that this E3 ligase adaptor interacts with the highly conserved cen-
tral rod domain, a region critically involved in regulating IF assem-
bly into higher-order structures through the formation of coil-coiled 
interactions (52, 53). Subsequently, in its role as an E3 ligase adap-
tor, gigaxonin could target the smallest disassembly units for degra-
dation. It is also possible that phosphorylation of vimentin may be 
involved in the process of its degradation by proteasomes, since the 
major known regulator of IF disassembly is phosphorylation (54–56). 
However, the state of vimentin phosphorylation in the presence of 
elevated gigaxonin remains unknown. Recent studies involving IF 
protein degradation in muscle atrophy provide additional insights 
into a possible relationship between phosphorylation and degrada-
tion of IF proteins (57). Specifically, desmin, the protein comprising 
the IF of skeletal muscle, was found to be phosphorylated, disassem-
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bled, and ubiquitinated by the E3 ligase TRIM32 and subsequently 
degraded (57). In contrast, our inability to detect ubiquitination 
of vimentin suggests that alternate mechanisms may be involved 
in targeting it to the proteasome. For example, gigaxonin may be 
involved in the ubiquitination of other proteins that bind to and 
target vimentin to the proteasome. In support of this possibility, 
it has previously been shown that direct target protein ubiquitina-
tion is not required for proteasomal degradation (58–61). Rather, 
an intermediate protein that is ubiquitinated binds to the target 
protein and escorts it to the proteasome for degradation. One of the 
best-studied examples of this type of pathway involves the human 
papilloma virus oncoprotein E7 and the degradation of its bind-
ing partner, the tumor-suppressor protein retinoblastoma (Rb) 
(62, 63). Therefore, Rb is not directly ubiquitinated, but is targeted 
to the proteasome by binding to ubiquitinated E7. A comparable 
mechanism may exist for the degradation of IF proteins mediated 
by gigaxonin. Nonetheless, the fact that gigaxonin is predicted to be 
an E3 ligase adaptor suggests that vimentin should become ubiqui-
tinated. However, it is well known that ubiquitination of a protein is 
often difficult to detect for numerous technical reasons, including 
specific deubiquitinase activity (64). Therefore, further studies are 
required to determine whether vimentin is ubiquitinated.
Although it is not known how gigaxonin is regulated in normal 
cells, it has previously been shown that it is expressed at extremely 
low levels (∼7,500 molecules/cell; ref. 20). In contrast, IF proteins 
such as vimentin can represent 2%–3% or more of total cell pro-
tein (65), yet only a small fraction appears to be in a soluble form 
(66). These limiting amounts of gigaxonin may therefore only be 
capable of targeting this small “soluble” pool of vimentin, which 
can then be degraded by the proteasome. In addition, the levels 
of gigaxonin in cells may be regulated at the transcriptional level 
and/or by its turnover. Better understanding of how gigaxonin is 
regulated is an essential element of understanding its role in the 
degradation of VIFs and of peripherin and NF IF proteins.
In summary, we identified gigaxonin as the first E3 ligase adaptor 
that targets cytoskeletal IF proteins for degradation. Our findings 
provided insight into the mechanisms responsible for the degrada-
tion of several major types of IF proteins and provided a framework 
for understanding the mechanisms responsible for the progressive 
neurological disorder GAN. Based on these findings, it is possible 
that the abnormal regulation of gigaxonin may also be involved in 
the numerous other diseases known to involve accumulations of IF 
and/or their constituent proteins, such as Alzheimer’s disease and 
Parkinson’s disease (see Introduction and refs. 3, 7).
Methods
Cell culture. BJ5ta human foreskin fibroblasts and NIH-3T3 mouse fibro-
blasts (ATCC) were maintained in DMEM (Invitrogen) supplemented with 
10% calf serum (HyClone). MEFs from control or Gan–/– mice (28) were 
cultured in DMEM containing 10% FCS. GAN patient fibroblast cell lines 
included F07476 (containing a 57- to 131-kb microdeletion, encompassing 
at least exons 3–11, as well as p.Glu486Lys in exon 9), 08F699 (containing 
the mutations IVS6_1g_a and L510X), and F09133 (containing the muta-
tions S52G and C393X) were obtained from R. Van Coster (Ghent University 
Hospital, Ghent, Belgium). These GAN cells were maintained in Medium 
199 (Invitrogen) supplemented with 10% FCS. Control skin fibroblasts 
from a 10-year-old female subject (AG08470; Coriell Institute for Medi-
cal Research) were grown in DMEM containing 10% FCS. PC12 cells were 
grown as previously described (67), and SH-SY-5Y cells (ATCC) were grown 
in DMEM (Invitrogen) supplemented with 10% FCS. Cell lines expressing 
recombinant proteins were maintained in their respective culture medium 
supplemented with 2 μg/ml puromycin (Sigma-Aldrich). Vim–/– MEFs (gift 
of J.E. Eriksson and E. Torvaldson, Åbo Akademi University, Turku, Finland) 
were grown in DMEM containing 10% FCS. PC12 cells were differenti-
ated with nerve growth factor (NGF; Invitrogen) as described previously 
(67–69). SH-SY-5Y cells were differentiated by culturing them in medium 
supplemented with 10 μM retinoic acid (RA; Sigma-Aldrich) for 1 week and 
then 10 μM RA plus 50 ng/ml brain-derived neurotrophic factor (BDNF; 
Sigma-Aldrich) for an additional week. Dorsal root ganglia (DRG) cultures 
were prepared from E13.5 embryos. DRGs were dissected and dissociated 
for 15 minutes at 37°C in 0.05% trypsin plus 0.53 mM EDTA (Invitrogen). 
After trypsinization, DRGs were rinsed with L-15 containing trypsin inhibi-
tor (1 mg/ml; Sigma-Aldrich) and then triturated. Neurons were plated onto 
4-well plates (LabTek) precoated with poly-d-lysine and extracellular matrix 
(Sigma-Aldrich) and maintained in neurobasal medium supplemented with 
B-27 supplement plus 0.5 mM glutamine and 15 ng/ml NGF. Culture media 
were supplemented with penicillin/streptomycin (Sigma-Aldrich), and all 
cell cultures were maintained at 37°C in a humidified CO2 incubator.
Antibodies and reagents. Mouse anti-vimentin, rat and mouse anti–α-tubulin, 
mouse anti–β-tubulin, rabbit anti-gigaxonin, rabbit anti-FLAG, mouse 
anti–NF-L, rabbit anti-TBCB, and mouse anti-actin were obtained from 
Sigma-Aldrich. Mouse anti-GAPDH (Biolegend), chicken anti-vimentin 
(Covance), rabbit anti–vimentin 314, and rabbit anti–peripherin 199 have 
been described previously (54, 70). Secondary antibodies included Alexa 
Fluor 488–, Alexa Fluor 568–, FITC-, and rhodamine-conjugated goat anti-
mouse, anti-chicken, and anti-rabbit IgG (Invitrogen). Secondary antibodies 
for immunoblotting included peroxidase-conjugated goat anti-mouse and 
anti-rabbit (Jackson ImmunoResearch). TRITC-conjugated phalloidin and 
Hoechst 33258 (Invitrogen) were used to stain actin and nuclei, respectively.
In some experiments, treatment with MG-132 (12 μM; Calbiochem; 10 or 
20 mg/ml stock in DMSO) was used to inhibit proteasomes, chloroquine 
(150 μM; Sigma-Aldrich) was used to inhibit lysosome function, and 3-MA 
(5 mM; Sigma-Aldrich) was used to inhibit autophagy. Cells were exposed to 
each of these inhibitors for 6–12 hours. In the MG-132 experiments, control 
cells were treated with a comparable concentration of DMSO.
DNA constructs. Plasmid vectors for eukaryotic expression of WT gigaxo-
nin (pTL3.1-gigaxonin) or mutant gigaxonin (pTL3.1–293X gigaxonin 
and pTL3.1–R138H gigaxonin) were previously described (10). The len-
tiviral vector pLEX-MCS–FLAG-tagged WT gigaxonin was generated as 
follows. FLAG-tagged gigaxonin was amplified by PCR using primers 
5′-CCCCCCACTAGTATGGACTACAAAGACGATGAC-3′ (forward) and 
5′-CCCCCCGCGGCCGCTCAAGGGGAATGAACACGAA-3′ (reverse). The 
PCR product was then digested with SpeI and NotI and cloned into the 
pLEX-MCS backbone that was previously digested with the same restric-
tion enzymes. The lentiviral vector expressing mutant FLAG-tagged S52G 
gigaxonin was prepared by introducing the 154A→G point mutation in the 
WT sequence of gigaxonin using the QuickChange Lightning Site-Directed 
Mutagenesis Kit (Stratagene). Lentiviral vectors coding for nontagged WT 
gigaxonin (pLEX-MCS gigaxonin) were prepared by digesting pTL3.1 with 
BamHI and NotI to release WT gigaxonin, then cloning it into the pLEX-MCS 
vector that had been double digested with BamHI and NotI.
FLAG-ΔC-VIM (vimentin with its non–α-helical C-terminal domain [aa 
1–411] deleted), FLAG-ΔN-VIM (vimentin with its non–α-helical N-terminal 
domain [aa 103–466] deleted), and FLAG-Rod-VIM (vimentin rod domain; aa 
103–411) were cloned into the lentiviral pLEX-MCS vector between BamHI 
and NotI sites using the InFusion HD Cloning System (Clontech). Each frag-
ment was amplified using Phusion High Fidelity Polymerase, and the FLAG 
tag was included in the 5′ primer for each deletion fragment. FLAG-FL-VIM 
(full-length vimentin), FLAG-Head-VIM (vimentin head domain only [aa 
1–102]), and FLAG-Tail-VIM (vimentin tail domain only [aa 411–466]) were 
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The ΔΔCt method was used for relative quantification, with GAPDH 
expression levels serving as reference (73). Each sample was run in triplicate, 
and any Ct values that diverged 4 or more cycles were excluded for subsequent 
analyses. Data represent average ± SD from 3 independent experiments.
ELISA. ELISA was carried out in 96-well Micro-test III assay plates 
(Falcon 3910; BD Labware) at room temperature on a Titer Plate shaker. 
Full-length vimentin and the vimentin rod domain (aa 103–411) were 
expressed in bacteria and purified as described previously (74). The wells 
of the microtiter plates were coated with 1 μg full-length vimentin or the 
rod domain in 100 μl PBS for 5 hours. The wells were then blocked 3 times 
with 0.05% Tween-20 in PBS (PBS-T; 300 μl/well) for 1 hour. To prepare cell 
extracts, FLAG-tagged gigaxonin expressing BJ5ta cells grown on a 100-mm 
dish were washed twice with 12 ml ice-cold Tris-buffered saline (TBS) and 
extracted with 1 ml PBS containing 1% Triton X-100, 0.5 M NaCl, 10 mM 
MgCl2, and protease inhibitors as above. The cell extracts (0–5 μg) in 100 μl 
of 0.5% BSA in PBS-T were overlaid and allowed to bind for 16 hours at 
room temperature. Wells were washed 3 times with PBS-T (300 μl/well) for 
30 minutes, and then rabbit anti-FLAG IgG (125 μl of 0.5 μg/ml) in PBS-T 
was added and allowed to bind for 2 hours at room temperature. The wells 
were washed 3 times with PBS-T (300 μl/well) and incubated with 125 μl 
alkaline phosphatase–conjugated anti-rabbit IgG (1:5,000 dilution in 
PBS-T containing 0.5% BSA) for 1 hour. The plates were then washed 
3 times with alkaline phosphatase buffer (100 mM Tris-HCl, 100 mM 
NaCl, 5 mM MgCl2, pH 9.5; 300 μl/well) for 30 minutes, and 100 μl of 
1 mg/ml p–nitrophenylphosphate disodium in the alkaline phosphatase 
buffer was added to each well. The developed color was read in a MRX 
Revelation microplate reader at 405 nm (Dynex Corp.). For controls, cell 
extracts were overlaid on BSA-coated wells (75).
In vitro ubiquitination assay. For substrate expression, we used the following 
constructs: pCDNA3-myc-VIM; pCDNA3–myc–Cullin-3 (Addgene catalog 
no. 19893; ref. 76); pET30A–WT gigaxonin. As a control, we used a con-
struct encoding sic 60–barnase–DHFR fusion — consisting of 60 aas from 
the bacterial Sic1 protein (containing a PPXY Rsp5 ubiquitination motif); 
followed by a catalytically inactive (H102A) Bacillus amyloliquefaciens barnase, 
with all lysine replaced by arginine, methionine, or alanine residues; fol-
lowed by E. coli dihydrofolate reductase (DHFR) — that has previously been 
used for ubiquitination and unfolding studies (77). Radioactive vimentin 
and control substrates (in pGEM3zf[+]) were expressed from a T7 promoter 
by in vitro transcription and translation using a TNT Coupled Reticulo-
cyte Lysate system (Promega) or an E. coli T7 S30 Extract system (Promega) 
containing [35S]-methionine. The ubiquitination reaction mixture con-
tained 100 nM UbE1, 200 ng UbcH5a (E2), 1 mg/ml ubiquitin, and 2 μM 
ubiquitin aldehyde (all from Boston Biochem); 20 mM creatine phosphate 
and 0.2 mg/ml creatine phosphokinase (both from Roche); 4 mM ATP 
(Sigma-Aldrich); and 1 μM DTT in ubiquitination buffer (25 mM Tris-Cl, 
pH 7.5; 50 mM NaCl; and 4 mM MgCl2), as described previously (78). In 
addition, in vitro–transcribed and –translated gigaxonin and Cullin-3 (sup-
plemented with nonradioactive methionine) or Rsp5 (E3) were added to 
assay for the ubiquitination of vimentin or the control substrates (77, 78). 
The reaction was incubated at 30°C for 90 minutes, and then samples were 
placed in Laemmli sample buffer and analyzed by SDS-PAGE. Radioactive 
proteins were detected by autoradiography (Instant Imager; Packard).
In vivo ubiquitination assay. In vivo ubiquitination was performed as 
described previously (79). In brief, HEK293T cells (100 mm) were cotrans-
ected with pCI-6xHis-Ub and FLAG-tagged gigaxonin or with FLAG-tagged 
gigaxonin and pCDNA3.1 (empty vector). 24 hours after transfection, cells 
were incubated with 10 μM MG-132 for 4 hours, then washed twice with 
PBS. Cell were extracted in 2 ml lysis buffer containing 50 mM Tris-HCl 
(pH 7.4), 0.25 M NaCl, 0.1% Triton X-100, 1 mM EDTA, 50 mM NaF, 1 mM 
DTT, 0.1 mM Na3VO4, inhibitor cocktail (Roche), 0.1 mM PMSF, and 2 mM 
amplified by PCR and cloned into pLEX-MCS vectors between BamHI and 
NotI sites. Individual clones were confirmed by sequencing.
Lentiviruses were produced according to the manufacturer’s instructions 
by cotransfecting plasmids pLEX-MCS (Thermo Scientific), along with the 
helper plasmids pVSVG and pAX2, into 293FT cells (Invitrogen) using Xfect 
Transfection Reagent (Clontech). Culture supernatant was collected 2 days 
later, and target cells were incubated with the viral supernatant supple-
mented with 8 μg/ml polybrene (Sigma-Aldrich) for 4–8 hours, after which 
the virus containing medium was replaced with the growth medium. This 
technique was used to establish 3T3 cell lines expressing FLAG-ΔN-VIM, 
FLAG-ΔC-VIM, and FLAG-rod-VIM constructs and Vim–/– cell lines express-
ing FLAG-ΔN-VIM, FLAG-ΔC-VIM, FLAG-rod-VIM, FLAG-Head-VIM, 
FLAG-Tail-VIM, and FLAG-FL-VIM constructs. In some cases, these lines 
were also infected with lentivirus expressing WT gigaxonin. Other lines 
used included BJ5ta, GAN 08F699, GAN F07476, 3T3, PC12, and SH-SY-5Y 
cells expressing WT gigaxonin and BJ5ta cells expressing S52G gigaxonin.
Immunofluorescence, image acquisition, and electron microscopy. Cells were 
processed for indirect single and double immunofluorescence after fixa-
tion in methanol or 3.7% formaldehyde as previously described (34, 50). 
The fixed, immunostained cells were imaged using a Zeiss confocal 
LSM510 META (Carl Zeiss) microscope with oil immersion objective lens-
es (Plan-Apochromat, ×63 and ×100, 1.40 NA; Carl Zeiss) (54). Electron 
microscopy was performed as previously described (71).
SDS-PAGE and immunoblotting. Cells grown in 60- or 100-mm culture 
dishes were lysed in Laemmli sample buffer, and proteins were separated 
by SDS-PAGE and immunoblotted as previously described (54, 72).
Image processing. Image J (NIH) and Photoshop CS3 (Adobe Systems) were 
used for figure preparation. Immunoblots were quantified using Kodak 
molecular imaging network software (Kodak).
IP experiments. Cell extracts for IP were prepared from BJ5ta cells expressing 
gigaxonin for 36 hours. 100-mm culture dishes were washed twice with ice-
cold PBS and then lysed on ice in 600 μl RIPA buffer (1% Triton X-100, 0.1% 
SDS, 0.5% sodium deoxycholate, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0) 
containing protease (EDTA-free mini tablets; Roche) and phosphatase 
inhibitors (Cocktail sets I & II; Calbiochem). The lysates were centrifuged 
at 20,000 g for 30 minutes, and the supernatants were removed in order to 
determine protein concentration using the BCA protein assay kit (Pierce; 
Thermo Scientific). The clarified supernatant was subjected to IP with pro-
tein A sepharose 4 fast flow resin (Amersham Biosciences) according to 
the manufacturer’s instructions. Briefly, 20 μg rabbit anti-gigaxonin IgG 
or anti-vimentin IgG was allowed to bind to approximately 100 μg of cell 
extract proteins in 1.5 ml of 100 mM sodium phosphate buffer (pH 7.0) for 
3 hours at 4°C and then mixed with protein A sepharose resin for another 
16 hours at 4°C. For controls, 20 μg normal rabbit/mouse IgG was used. 
The resin was washed thoroughly, and samples were boiled in SDS-PAGE 
sample buffer. Mouse monoclonal anti-vimentin IgG or rabbit anti-gigax-
onin IgG were used for immunoblotting after SDS-PAGE.
mRNA analysis. Total RNA was prepared from cells using TRIzol 
(Invitrogen) and further purified to remove any contaminating DNA 
(RNeasy kit; Invitrogen). For quantitative RT-PCR, 1 μg total RNA 
was used to generate cDNA with the SuperScript III First-Strand kit 
(Invitrogen), and 1 μl of the total reaction volume was used for quanti-
tative RT-PCR. All amplifications were performed on a Mastercyler EP 
Realplex (Eppendorf) using a master-mix containing SYBR Green and Rox 
(Applied Biosystem). RNA expression levels were analyzed using the fol-
lowing primers: VIM forward, 5′-AAGAGAACTTTGCCGTTGAA-3′; VIM 
reverse, 5′-GTGATGCTGAGAAGTTTCGT-3′; GAPDH forward, 5′-CTG-
CACCACCAACTGCTTAG-3′; GAPDH reverse, 5′-AGGTCCACCACT-
GACACGTT-3′; GAN forward, 5′-GGGTAGCGAGATGGTAACTTG-3′; 
GAN reverse, 5′-CGGATGGAAGGAGTGGTTTAG-3′.
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N-ethylmaleimide (NEM; isopeptidase and deubiquitinase inhibitor). 
Next, 100 μl prewashed Talon magnetic beads (Clontech) were added to 
the cell extract to a total volume of 6 ml and rotated for 2 hours at 4°C. 
Beads were washed twice in lysis buffer followed by an additional wash 
with lysis buffer containing 10 mM imidazole. Next, protein was eluted 
with 250 mM imidazole in lysis buffer, added to Laemmli sample buffer, 
and loaded on SDS-PAGE for detection of vimentin by Western blot.
Statistics. Data represent average ± SD from at least 3 independent experi-
ments. 2-tailed Student’s t tests were carried out to assess the significance 
of the results. A P value of 0.01 or less was considered significant.
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